Skip to ContentSkip to Navigation
How to find us prof. dr. W. (Wim) Timens


Abnormalities in reparative function of lung-derived mesenchymal stromal cells in emphysema

Detecting therapy-guiding RNA aberrations in platelets of non-small cell lung cancer patients

F-18-FDG PET/CT Scans Can Identify Sub-Groups of NSCLC Patients with High Glucose Uptake in the Majority of Their Tumor Lesions

Genome-wide association meta-analysis identifies pleiotropic risk loci for aerodigestive squamous cell cancers

Multi-omics highlights ABO plasma protein as a causal risk factor for COVID-19

New insights in phenotype and treatment of lung disease immuno-deficiency and chromosome breakage syndrome (LICS)

Non-small-cell lung cancer infiltrated with chronic myelomonocytic leukaemia: a molecular diagnostic challenge to recognise mixed cancers in a single biopsy

Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy

A case report of an unusual non-mucinous papillary variant of CPAM type 1 with KRAS mutations

A homozygous variant in growth and differentiation factor 2(GDF2)may cause lymphatic dysplasia with hydrothorax and nonimmune hydrops fetalis

Read more


Covid2019: ACE2-receptor speelde ook grote rol bij SARS.

Revival van de Dutch Hypothesis, in geïndividualiseerde vorm.

Pathologisch onderzoek essentieel voor kankerdiagnose

Kankercellen onder de loep

Zien welke kanker het is

PD-L1 kleuring vereist bij eerstelijnsbehandeling urotheelcarcinoom met pembrolizumab

Longkanker, welke vorm heb ik? Patiënteninformatieboekje Longkanker.

Read more